CURRICULUM VITAE

Name: Morris Schambelan, MD

Address: Division of Endocrinology
Building 30, Room 3501K
San Francisco General Hospital
San Francisco, CA 94110

Education:

1955-1958 University of Pennsylvania, Philadelphia, PA; AB (1958)

1958-1962 University of Pennsylvania, Philadelphia, PA; MD (1962)

Research and Professional Experience:

1962-1963 Intern, San Francisco General Hospital (SFGH)

1963-1965 Medical Officer, US Naval Reserve, Active Duty

1966 Research Physician, International Cardiology Foundation, L'Hopital Schweitzer, Lambarene, Gabon, West Africa

1966-1968 NIH Postdoctoral Research Fellow, Division of Endocrinology and General Clinical Research Center (GCRC), SFGH

1968-1970 Assistant Resident, Department of Internal Medicine, University of California, San Francisco (UCSF)

1970-1971 Chief Resident, Medical Service, SFGH

1971-1975 Assistant Professor of Medicine in Residence, UCSF

1971-1980 Assistant Program Director, GCRC, SFGH

1976-1983 Associate Professor of Medicine in Residence, UCSF

1976-1985 Assistant Chief, Division of Endocrinology, SFGH

1980-1992 Associate Program Director, GCRC, SFGH

1983-1994 Professor of Medicine in Residence, UCSF

Research and Professional Experience (continued):

1985-present	Chief, Division of Endocrinology, SFGH
1992-present	Program Director, GCRC, SFGH
1994-present	Professor of Medicine, UCSF

Medical License and Board Certificates:

1965	California Medical License
1975	Diplomat, American Board of Internal Medicine
1975	Subspecialty Board, Endocrinology and Metabolism

Societies:

American Association for the Advancement of Science
American Diabetes Association
American Federation for Clinical Research
American Physiological Society
American Society for Clinical Investigation
American Society of Hypertension
American Society of Nephrology
Association of American Physicians
Endocrine Society
International Society of Hypertension
International Society of Nephrology

Western Association of Physicians
Western Society for Clinical Research

Editorial Positions:

1981-1984	Member of Editorial Board, Journal of Clinical Endocrinology and Metabolism
1985-1988	Member of Editorial Board, American Journal of Physiology: Endocrinology and Metabolism

Federal Government Advisory Committees:

1984	Ad Hoc Reviewer, Cardiovascular/Renal Study Section, NIH
1987-1991	Member, Cardiovascular/Renal Study Section, NIH\

MORRIS SCHAMBELAN, M.D.

Publications in Journals

1. Schambelan M, S Sussman: Encephalitis and purpura with influenza infection. *Am J Dis Child* 111:302-303, 1966.

2. Biglieri EG, PE Slaton, SJ Kronfield, M Schambelan: Diagnosis of aldosterone-producing adenoma in primary aldosteronism. *JAMA* 201:510-514, 1967.

3. Biglieri EG, PE Slaton, M Schambelan, SJ Kronfield: Hypermineralocorticoidism. *Am J Med* 45:170-175, 1968.

4. Slaton PE, M Schambelan, EG Biglieri: Stimulation and suppression of aldosterone secretion in patients with an aldosterone-producing adenoma. *J Clin Endocrinol Metab* 29:239-250, 1969.

5. Schambelan M, PE Slaton, JF Murray, EG Biglieri: Adrenal insufficiency and inappropriate secretion of antidiuretic hormone. *Arch Intern Med* 124:197-201, 1969.

6. Biglieri EG, M Schambelan, PE Slaton: Effect of adrenocortico-tropin on deoxycorticosterone, corticosterone, and aldosterone excretion. *J Clin Endocrinol Metab* 29:1090-1101, 1969.

7. Biglieri EG, M Schambelan, PE Slaton, JR Stockigt: The intercurrent hypertension of primary aldosteronism. *Circ Res* 26-27 (Suppl. I): I195-I202, 1970.

8. Biglieri EG, JR Stockigt, M Schambelan: A preliminary evaluation for primary aldosteronism. *Arch Intern Med* 126:1004-1007, 1970.

9. Schambelan M, PE Slaton Jr, EG Biglieri: Mineralocorticoid production in hyperadrenocorticism: role in pathogenesis of hypokalemic alkalosis. *Am J Med* 51:299-303, 1971.

10. Biglieri EG, JR Stockigt, M Schambelan: Mineralocorticoid hypertension. *Excerpta Med Int Congr Series* 219:565-571, 1971.

11. Schambelan M, EG Biglieri: Deoxycorticosterone production and regulation in man. *J Clin Endocrinol Metab* 34:695-703, 1972.

12. Schambelan M, JR Stockigt, EG Biglieri: Isolated hypoaldosteronism in adults: a renin-deficiency syndrome. *N Engl J Med* 287:573-578, 1972.

13. Biglieri EG, JR Stockigt, M Schambelan: Adrenal mineralocorticoids causing hypertension. *Am J Med* 52:623-632, 1972.

14. Stockigt JR, RD Collins, C Noakes, M Schambelan, EG Biglieri: Renal-vein renin in various forms of renal hypertension. *Lancet* 1:1194-1198, 1972.

Journals

15. Schambelan M, JR Stockigt, EG Biglieri: Hyperkalemia and renin production. *N Engl J Med* 287:1151, 1972.

16. Schambelan M: Medical Staff Conference: Isolated hypoaldosteronism. *Calif Med* 118:33-38, 1973.

17. Schambelan M, EG Biglieri: Renin-secreting tumor as a cause of hypertension. *Excerpta Med Int Congr Series* 273:757-760, 1973.

18. Stockigt JR, P Hertz, M Schambelan, EG Biglieri: Segmental renal-vein renin sampling for segmental renal infarction. Studies in a hypertensive patient. *Ann Intern Med* 79:67-70, 1973.

19. Schambelan M, EL Howes, JR Stockigt, CA Noakes, EG Biglieri: Role of renin and aldosterone in hypertension due to a renin- secreting tumor. *Am J Med* 55:86-92, 1973.

20 Eichner H, M Schambelan, EG Biglieri: Systemic lupus erythematosus with adrenal insufficiency. *Am J Med* 55:700-705, 1973.

21. Schambelan M: Hypertension resulting from a renin-secreting tumor. *Hypertension Rev.* 1:1-2. 1973.

22. Golde DW, M Schambelan, BD Weintraub, SW Rosen: Gonadotropin-secreting renal carcinoma. *Cancer* 33:1048-1053, 1974.

23. Biglieri EG, M Schambelan, N Brust, B Chang, M Hogan: Plasma aldosterone concentration: further characterization of aldosterone producing adenomas. *Circ Res* 34,35 (Suppl. I): I-183-I-191, 1974.

24. Schambelan M, M Glickman, JR Stockigt, EG Biglieri: Selective renal-vein renin sampling in hypertensive patients with segmental renal lesions. *N Engl J Med* 290:1153-1157, 1974.

25. Clark OH, AD Hall, M Schambelan: Clinical manifestations of adrenal hemorrhage. *Am J Surg* 128:219-224, 1974.

26. Schambelan M, EG Biglieri: Test for role of angiotensin in hypertension. *N Engl J Med* 291:258, 1974.

27. Schambelan M: Medical Staff Conference: Inappropriate antidiuretic hormone secretion. *West J Med* 122:145-149, 1975.

28. Hunt TK, M Schambelan, EG Biglieri: Selection of patients and operative approach in primary aldosteronism. *Ann Surg* 182:353-361, 1975.

Journals

29. Hogan MJ, J McRae, M Schambelan, EG Biglieri: Location of aldosterone-producing adenomas with ^{131}I-19-iodocholesterol. *N Engl J Med* 294:410-414, 1976.

30. Korobkin M, MG Glickman, M Schambelan: Segmental renal vein sampling for renin. *Radiology* 118:307-313, 1976.

31. Schambelan M, NL Brust, BCF Chang, KL Slater, EG Biglieri: Circadian rhythm and effect of posture on plasma aldosterone concentration in primary aldosteronism *J Clin Endocrinol Metab* 43:115-131, 1976.

32. Baxter JD, M Schambelan, DT Matulich, BJ Spindler, AA Taylor, FC Bartter: Aldosterone receptors and the evaluation of plasma mineralocorticoid activity in normal and hypertensive states. *J Clin Invest* 58:579-589, 1976.

33. Baxter JD, M Schambelan, DT Matulich, BJ Spindler, FC Bartter: Role of steroids in hypertension: evaluation of plasma mineralocorticoid activity with aldosterone receptors. *Clin Sci Mol Med* 51 (Suppl. 3):321s-324s, 1976.

34. Matulich DT, BJ Spindler, M Schambelan, JD Baxter: Mineralocorticoid receptors in human kidney. *J Clin Endocrinol Metab* 43:1170-1174, 1976.

35. Kershnar AK, D Borut, MD Kogut, EG Biglieri, M Schambelan: Studies in a phenotypic female with 17a-hydroxylase deficiency. *J Pediatr* 89:395-450, 1976.

36. Potter DE, M Schambelan, O Salvatierra Jr, S Orloff, MA Holliday: Treatment of high-renin hypertension with propranolol in children after renal transplantation. *J Pediatr* 90:307-311, 1977.

37. Sebastian AS, M Schambelan, S Lindenfeld, RC Morris Jr: Amelioration of metabolic acidosis with fludrocortisone therapy in patients with hyporeninemic hypoaldosteronism. *N Engl J Med* 297:576-583, 1977.

38. Hogan MJ, M Schambelan, EG Biglieri: Concurrent hypercortisolism and hypermineralocorticoidism. *Am J Med* 62:777-782, 1977.

39. Biglieri EG, M Schambelan, J Hirai, B Chang, N Brust: The significance of elevated levels of plasma 18-hydroxycorticosterone in patients with primary aldosteronism. *J Clin Endocrinol Metab* 49:87-91, 1979.

40. Biglieri EG, B Chang, J Hirai, N Brust, CR Rost, M Schambelan: Adrenocorticotropin inhibition of mineralocorticoid hormone production. *Clin Sci Mol Med* 57 (Suppl. 5): 307s-311s, 1979.

41. Schambelan M, A Sebastian: Hyporeninemic hypoaldosteronism. *Adv Intern Med* 24:385-405, 1979.

Journals

42. Schambelan M, A Sebastian, EG Biglieri: Prevalence, pathogenesis, and functional significance of aldosterone deficiency in hyperkalemic patients with chronic renal insufficiency. *Kidney Int* 17:89-101, 1980.

43. White RH, M Schambelan: Hypertension, hyperreninemia, and secondary hyperaldosteronism in systemic necrotizing vasculitis. *Ann Intern Med.* 92:199-201, 1980.

44. Benowitz NL, R Byrd, M Schambelan, J Rosenberg, MF Roizen: Dihydroergotamine treatment for severe orthostatic hypotension secondary to vacor rodenticide ingestion. *Ann Intern Med* 92:387-388, 1980.

45. Hulter HN, A Sebastian, JF Sigala, JH Licht, RD Glynn, M Schambelan, EG Biglieri, JA Harbottle, LP Ilnicki, B Chang: Pathogenesis of renal hyperchloremic acidosis resulting from dietary potassium restriction in the dog: role of aldosterone. *Am J Physiol* 238:F79-F91, 1980.

46. Sebastian A, JM Sutton, HN Hulter, M Schambelan, SM Poler: Effect of mineralocorticoid replacement therapy on renal acid-base homeostasis in adrenalectomized patients. *Kidney Int* 18:762-773, 1980.

47. White EA, M Schambelan, CR Rost, EG Biglieri, AA Moss, M Korobkin: Use of computed tomography in diagnosing the cause of primary aldosteronism. *N Engl J Med* 303:1503-1507, 1980.

48. Biglieri EG, N Brust, B Chang, J Hirai, BL Wajchenberg, M Schambelan: Clinical manifestations of adrenocorticotropin-determined plasma concentrations of mineralocorticoid hormones. *Prog Biochem Pharmaco* 17:36-43, 1980.

49. Schambelan M, A Sebastian, and FC Rector Jr: Mineralocorticoid-resistant hyperkalemia without salt wasting (type II pseudohypoaldosteronism): role of increased renal chloride reabsorption. *Kidney Int* 19:716-727, 1981.

50. Humphreys MH, H Al-Bander, JF Eneas, M Schambelan: Factors determining electrolyte excretion and renin secretion following closure of an arteriovenous fistula in the dog. *J Lab Clin Med* 98:89-98, 1981.

51. Rodriquez JA, EG Biglieri, M Schambelan: Pseudohyperaldosteronism with renal tubular resistance to mineralocorticoid hormones. *Trans Assoc Am Physicians* 94:172-182, 1981.

52. Schambelan M, AA Moss, EG Biglieri: Computed tomography to determine the cause of primary aldosteronism. *N Engl J Med* 304:1047, 1981.

53. Sebastian A, HN Hulter, I Kurtz, T Maher, M Schambelan: Disorders of distal nephron function. *Am J Med* 72:289-307, 1982.

Journals

54. Jones JW, A Sebastian, HN Hulter, M Schambelan, JM Sutton, EG Biglieri: Systemic and renal acid-base effects of chronic dietary K^+ depletion in humans. *Kidney Int* 21:402-410, 1982.

55. Kirby BD, J Ham, HB Fairley, N Benowitz, M Schambelan: Normotensive pheochromocytoma: Pharmacologic, paraneoplastic and anesthetic considerations. *West J Med* 139:221-225, 1983.

56. Landefeld CS, M Schambelan, SL Kaplan, SH Embury: Clomiphene-responsive hypogonadism in sickle cell anemia. *Ann Intern Med* 99:480-483, 1983.

57. Kurtz I, T Maher, HN Hulter, M Schambelan, A Sebastian: Effect of diet on plasma acid-base composition in normal humans. *Kidney Int* 24:670-680, 1983.

58. Williams FA, M Schambelan, EG Biglieri, RM Carey: Acquired primary hypoaldosteronism due to an isolated zona glomerulosa defect. *N Engl J Med* 309:1623-1626, 1983.

59. Ardaillou N, M-P Nivez, M Schambelan, R Ardaillou: Response of adenylate cyclase to parathyroid hormone and prostaglandins by human isolated glomeruli. *J Clin Endocrinol Metab* 57:1207-1215, 1983.

60. Kater CE, EG Biglieri, M Schambelan, EA Arteaga: Studies of the impaired aldosterone response to spironolactone-induced renin and potassium elevations. *Hypertension* 5 (Suppl.V): V115-V121, 1983.

61. Carey RW, M Schambelan, EG Biglieri, GM Bright: Primary hypoaldosteronism due to zona glomerulosa defect. *N Engl J Med* 310:1394, 1395, 1984.

62. Maher T, M Schambelan, I Kurtz, HN Hulter, JW Jones, A Sebastian: Amelioration of metabolic acidosis by dietary potassium restriction in hyperkalemic patients with chronic renal insufficiency. *J Lab Clin Med* 103:432-445, 1984.

63. Sebastian A, M Schambelan, JM Sutton: Amelioration of hyperchloremic acidosis and hyperkalemia with furosemide therapy in patients with chronic renal insufficiency and type 4 renal tubular acidosis. *Am J Nephrol* 4:287-300, 1984.

64. Arteaga E, EG Biglieri, CE Kater, JM Lopez, M Schambelan: Aldosterone-producing adrenocortical carcinoma: Preoperative recognition and course in three cases. *Ann Int Med* 101:316-321, 1984.

65. Schambelan M, A Sebastian, EG Biglieri, R Hernandez: Interaction of potassium and the renin-angiotensin system in the control of aldosterone secretion in normal and pathophysiologic states. *Excerpta Med Int Cong Series* 655:217-220, 1984.

Journals

66. Kater CE, EG Biglieri, CR Rost, M Schambelan, J Hirai, BCF Chang, N Brust: The constant plasma 18-hydroxycorticosterone:aldosterone ratio. An expression of the efficacy of corticosterone methyloxidase type II activity in disorders with variable aldosterone production. *J Clin Endocrinol Metab* 60:225-228, 1985.

67. Schambelan M, S Blake, J Sraer, M Bens, M-P Nivez, F Wahbe: Increased prostaglandin production by glomeruli isolated from rats with streptozotocin-induced diabetes mellitus. *J Clin Invest* 75:404-412, 1985.

68. Schambelan M, A Sebastian: Acidose renale tubulaire de type IV: role pathogene du deficit en aldosterone et de l'hyperkaliemie. *Nephrologie* 6:135-137, 1985.

69. Lim RC, DK Nakayama, EG Biglieri, M Schambelan, TK Hunt: Primary aldosteronism: changing concepts in diagnosis and management. *Amer J Surg* 152:116-121, 1986.

70. Schambelan M, A Sebastian, BA Katuna, E Arteaga: Adrenocortical hormone secretory response to chronic $NHCl_4$-induced metabolic acidosis. *Am J Physiol* 252:E454-E460, 1987.

71. Hernandez RE, M Schambelan, MG Cogan, J Colman, RC Morris Jr, A Sebastian: Dietary NaCl determines severity of potassium depletion-induced metabolic acidosis. *Kidney Int* 31:1356-1367, 1987.

72. Schambelan M, A Sebastian: Pathogenesis and pathophysiologic role of hypoaldosteronism in syndromes of renal hyperkalemia. *Current Topics in Membranes and Transport* 28:351-366, 1987.

73. Hutchinson FN, BR Don, GA Kaysen, S Blake, M Schambelan: Dietary protein intake modulates glomerular eicosanoid production in nephrotic rats. *Adv in Prostaglandins, Thromboxane, and Leukotriene Res* 17:725-728, 1987.

74. Hutchison F, M Schambelan, G Kaysen: Modulation of albuminuria by dietary protein and converting enzyme inhibition. *Am J Physiol* 253:F719-F725, 1987.

75. Don BR, M Schambelan: Medical Staff Conference: Diabetes, dietary protein and glomerular hyperfiltration. *West J Med* 147:449-455, 1987.

76. Sebastian A, and M Schambelan: Renal hyperkalemia. *Seminars Nephrol* 7:223-238, 1987.

77. Toffelmire EB, K Slater, P Corvol, J Menard, M Schambelan: Response of plasma prorenin and active renin to chronic and acute alterations of renin secretion in normal humans: Studies using a direct immunoradiometric assay. *J Clin Invest* 83:679-687, 1989.

Journals

78. Don BR, S Blake, FN Hutchison, GA Kaysen, M Schambelan: Dietary protein modulates glomerular eicosanoid production in the rat. *Am J Physiol* 256:F711-F718, 1989.

79. Noth RH, AS Krolewski, GA Kaysen, TW Meyer, M Schambelan: Diabetic nephropathy: Hemodynamic basis and implications for disease management. *Ann Intern Med* 110:795-813, 1989.

80. Don BR, L Wada, GA Kaysen, M Schambelan: Effect of dietary protein restriction and angiotensin converting enzyme inhibition on protein metabolism in the nephrotic syndrome. *Kidney Int* 36 (Suppl. 27):S163-S167, 1989.

81. Denolle T, V Rohmer, JP Saint-Andre, TT Guyene, F Galland, JC Bigorgne, M Schambelan, P Corvol: Effect of the circulating renin-angiotensin system on prolactin release in humans. *J Clin Endocrinol Metab* 70:288-292, 1990.

82. Don BR, A Sebastian, M Cheitlin, M Christiansen, M Schambelan: Pseudohyperkalemia caused by fist clenching during phlebotomy. *N Engl J Med* 322:1290-1292, 1990.

83. Farese RV JR, M Schambelan, H Hollander, S Stringari, MA Jacobson: Nephrogenic diabetes insipidus associated with foscarnet treatment of cytomegalovirus retinitis in a patient with acquired immunodeficiency syndrome. *Ann Intern Med* 112:955-956, 1990.

84. Don BR, M Schambelan: Hyperkalemia in acute glomerulonephritis due to transient hyporeninemic hypoaldosteronism. *Kidney Int* 38:1159-1163, 1990.

85. Anderson PA, YS Do, M Schambelan, R Horton, RS Boger, RR Luther, WA Hsueh: Effects of renin inhibition in systemic hypertension. *Am J Cardiol* 66:1342-1347, 1990.

86. Don BR, GA Kaysen, FN Hutchison, M Schambelan: The effect of angiotensin converting enzyme inhibition and dietary protein restriction in the treatment of proteinuria. *Am J Kidney Dis* 17:10-17, 1991.

87. Kaysen GA, BR Don, M Schambelan: Proteinuria, albumin synthesis and hyperlipidemia in the nephrotic syndrome. *Nephrol Dial Transplant* 6:141-149, 1991.

88. Wada L, BR Don, M Schambelan: Hormonal mediators of amino acid-induced glomerular hyperfiltration in humans. *Am J Physiol* 260:F787-F792, 1991.

89. Grady EF, LA Sechi, CA Griffin, M Schambelan, JE Kalinyak: Expression of type 2 angiotensin II receptors in the developing rat fetus. *J Clin Invest* 88:921-933, 1991.

90. Sechi LA, EF Grady, CA Griffin, JE Kalinyak, M Schambelan: Insulin receptor concentration and gene expression are modulated by sodium intake in the rat kidney. *J Hypertens* 9 (Suppl.6): S212-S217, 1991.

Journals

91. Sechi LA, EF Grady, CA Griffin, JE Kalinyak, M Schambelan: Characterization of angiotensin II receptor subtypes in the rat kidney and heart using the nonpeptide antagonists DuP 753 and PD 123177. *J Hypertens* 9 (Suppl.6): S224-S225, 1991.

92. Sechi LA, EF Grady, CA Griffin, JE Kalinyak, M Schambelan: Distribution of angiotensin II receptor subtypes in rat and human kidney. *Am J Physiol* 262: F236-F240, 1992.

93. Al-Uzri A, MA Holliday, JG Gambertoglio, M Schambelan, BA Kogan, BR Don: An accurate practical method for estimating GFR in clinical studies using a constant subcutaneous infusion. *Kidney Int* 41:1701-1706, 1992.

94. Sechi LA, CA Griffin, EF Grady, C Grunfeld, JE Kalinyak, M Schambelan: Tissue-specific regulation of insulin receptor mRNA levels in rats with STZ-induced diabetes mellitus. *Diabetes* 41:1113-1118, 1992.

95. Ray PE, M Schambelan, R Hintz, EJ Ruley, J Harrah, MA Holliday: Plasma renin activity as a marker for growth failure due to sodium deficiency in young rats. *Pediatr Nephrol* 6:523-526, 1992.

96. Sechi LA, CA Griffin, EF Grady, JE Kalinyak, M Schambelan: Characterization of angiotensin II receptor subtypes in rat heart. *Circ Res* 71:1482-1489, 1992.

97. Valentin J-P, LA Sechi, C Qiu, M Schambelan, MH Humphreys: Urodilatin binds to and activates renal receptors for atrial natriuretic peptide. *Hypertension* 21:432-438, 1993.

98. Sechi LA, G Sechi, S De Carli, CA Griffin, M Schambelan, E Bartoli: Studio dei recettori dell'angiotensina nel miocardio di ratto durante lo sviluppo pre- e post-natale. *Cardiologia* 38:471-476, 1993.

99. Sechi LA, J-P Valentin, CA Griffin, M Schambelan: Autoradiographic characterization of angiotensin II receptor subtypes in rat intestine. *Am J Physiol* 265:G21-G27, 1993.

100. Mulligan KM, C Grunfeld, MK Hellerstein, RA Neese, M Schambelan: Anabolic effects of recombinant human growth hormone in patients with wasting associated with human immunodeficiency virus infection. *J Clin Endocrinol Metab* 77:956-962, 1993.

101. Kalinyak JE, LA Sechi, CA Griffin, BR Don, K Tavangar, FB Kraemer, AR Hoffman, M Schambelan: The renin-angiotensin system in streptozotocin-induced diabetes mellitus in the rat. *J Am Soc Nephrol* 4:1337-1345, 1993.

102. Sechi LA, CA Griffin, S DeCarli, G Sechi, M Schambelan, E Bartoli: I recettori dell'angiotensina II nel tessuto di conduzione cardiaco. *Minerva Cardioangiologica* 41:511-516, 1993.

Journals

103. Sechi LA, G Sechi, S De Carli, CA Griffin, M Schambelan, E Bartoli: Ruolo di proteine-G regolatrici nel meccanismo intracellulare dei recettori cardiaci dell'angiotensina II. *Cardiologia* 38:519-523, 1993.

104. Valentin J-P, LA Sechi, CA Griffin, M Humphreys, M Schambelan: Renin-angiotensin system gene expression during compensatory renal hypertrophy in the rat. *J Hypertens* 11(Suppl. 6):S236-S237, 1993.

105. Masharani U, M Schambelan: The endocrine complications of AIDS. *Adv Intern Med* 38:323-336, 1993.

106. Schambelan M: Licorice ingestion and blood pressure regulating hormones. *Steroids* 59:127-130, 1994.

107. Sechi LA, CA Griffin, M Schambelan: Effect of dietary sodium chloride on insulin receptor number and mRNA levels in rat kidney. *Am J Physiol* 266:F31-38, 1994.

108. Sechi LA, CA Griffin, M Schambelan: The cardiac renin-angiotensin system in STZ-induced diabetes mellitus. *Diabetes* 43:1180-1184, 1994.

109. Shimkets RA, DG Warnock, CM Bositis, C Nelson-Williams, JH Hansson, M Schambelan, JR Gill Jr, S Ulick, RV Milera, JW Findling, CM Canessa, BC Rossier, RP Lifton: Liddle's syndrome: heritable human hypertension caused by mutations in the β subunit of the epithelial sodium channel. *Cell* 79:407-414, 1994.

110. Valentin JP, LA Sechi, CA Griffin, MH Humphreys, M Schambelan: Expression des gènes du système rénine-angiotensine lors de l'hypertrophie compensatrice rénale secondaire à la néphrectomie controlatérale. *Arch Mal Coeur* 87:1115-1117, 1994.

111. Sechi LA, J-P Valentin, CA Griffin, E Lee, E Bartoli, MH Humphreys, M Schambelan: Receptors for atrial natriuretic peptide are decreased in the kidney of rats with streptozotocin-induced diabetes mellitus. *J Clin Invest* 95:2451-2457, 1995.

112. Jeunemaitre X, A Charru, L Pascoe, TT Guyene, B Aupetit-Faisant, CHL Shackleton, M Schambelan, PF Plouin, P Corvol: Hyperaldosteronisme sensible a la dexamethasone avec adenome surrenalien: etude clinique, biologique et genetique. *Presse Medicale* 24:1243-1248, 1995.

113. Papadakis MA, D Grady, D Black, MJ Tierney, GAW Gooding, M Schambelan, C Grunfeld: Growth hormone replacement in healthy older men improves body composition but not functional ability. *Ann Intern Med* 124:708-716, 1996.

Journals

114. Sechi LA, CA Griffin, G Giacchetti, L Zingaro, C Catena, E Bartoli, M Schambelan: Abnormalities of insulin receptors in spontaneously hypertensive rats. *Hypertension* 27:955-961, 1996.

115. Benowitz N, S Zevin, S Carlsen, J Hayes, M Schambelan, M Cheitlin: Orthostatic hypertension due to vascular adrenergic hypersensitivity. *Hypertension* 28:42-46, 1996.

116. Sechi LA, CA Griffin, G Giacchetti, J-P Valentin, C Llorens-Cortes, P Corvol, M Schambelan: Tissue-specific regulation of type 1 angiotensin II receptor mRNA levels in the rat. *Hypertension* 28:403-408, 1996.

117. Schambelan M, K Mulligan, C Grunfeld, ES Daar, A LaMarca, DP Kotler, J Wang, SA Bozzette, JB Breitmeyer: Recombinant human growth hormone in patients with HIV-associated wasting: A randomized placebo-controlled trial. *Ann Intern Med* 125:873-882, 1996.

118. Meiner VL, S Cases, HM Myers, ER Sande, S Bellosta, M Schambelan, RE Pitas, J McGuire, J Herz, RV Farese, Jr: Disruption of the acyl CoA:cholesterol acyltransferase (ACAT) gene in mice: Evidence suggesting multiple cholesterol esterification enzymes in mammals. *Proc Nat Acad Sci* 93:14041-14046, 1996.

119. Mulligan K, VW Tai, and M Schambelan: Energy expenditure in human immunodeficiency virus infection. *N Engl J Med* 336:70-71, 1996.

120. Mulligan K, M Schambelan, C Grunfeld: Repletion of lean body mass using growth factors in patients with HIV-associated wasting. *Nutr Clin Metabol* 10:337-346, 1997.

121. Griffin CA, G Giacchetti, M Schambelan, LA Sechi: Ontogenic regulation of renal and hepatic angiotensin II receptor gene expression in the rat. *Nephron* 76:103-110, 1997

122. Valentin J-P, LA Sechi, CA Griffin, MH Humphreys, M Schambelan: The renin-angiotensin system and compensatory renal hypertrophy in the rat. *Am J Hypertens* 10:397-402, 1997.

123. Sechi LA, A Ceriello, CA Griffin, C Catena, P Amstad, M Schambelan, E Bartoli: Renal antioxidant enzyme mRNA levels are increased in rats with experimental diabetes mellitus. *Diabetologia* 40:23-29, 1997.

124. Mulligan K, VW Tai, M Schambelan: Cross-sectional and longitudinal evaluation of body composition in HIV-infected men. *J Acquir Immune Defic Syndr* 15:43-48, 1997.

Journals

125. Sechi LA, CA Griffin, L Zingaro, J-P Valentin, E Bartoli, M Schambelan: Effects of angiotensin II on insulin receptor binding and mRNA levels in normal and diabetic rats. *Diabetologia* 40:770-777, 1997.

126. Deeks SG, RL Coleman, R White, C Pachl, M Schambelan, DN Chernoff, MB Feinberg: Variance of plasma human immunodeficiency virus type 1 RNA levels measured by branched DNA within and between days. *J Infect Dis* 176:514-517, 1997.

127. Sechi LA, CA Griffin, L Zingaro, C Catena, S DeCarli, M Schambelan, E Bartoli: Glucose metabolism and insulin receptor binding and mRNA levels in tissues of Dahl hypertensive rats. *Am J Hypertens* 10:1223-1230, 1997.

128. Johansen KL, K Mulligan, VW Tai, M Schambelan: Leptin, body composition, and indices of malnutrition in patients on dialysis. *J Am Soc Nephrol* 9:1080-1084, 1998.

129. Lo JC, K Mulligan, VW Tai, H Algren, M Schambelan: Buffalo hump in HIV-infected patients on antiretroviral therapy. *Lancet* 351:867-870, 1998.

130. Mulligan K, VW Tai, M Schambelan: Effects of chronic growth hormone treatment on energy intake and resting energy metabolism in patients with human immunodeficiency virus-associated wasting: a clinical research center study. *J Clin Endocrinol Metab* 83:1542-1547, 1998.

131. Engler MM, M Schambelan, MB Engler, DL Ball, TL Goodfriend: Effects of dietary gamma-linolenic acid on blood pressure and adrenal angiotensin receptors in hypertensive rats. *Proc Soc Exp Biol Med* 218:234-237, 1998.

132. Lo JC, K Mulligan, VW Tai, H Algren, M Schambelan: Body shape changes in HIV-infected patients. *J Acquir Immune Defic Syndr* 19:307-308, 1998.

133. Johansen KL, K Mulligan, M Schambelan: Anabolic effects of nandrolone decanoate in patients receiving dialysis: A randomized controlled trial. *JAMA* 281:1275-1281, 1999.

134. Westphal CH, L Muller, A Zhou, X Zhu, S Bonner-Weir, M Schambelan, DF Steiner, I Lindberg, P Leder: The neuroendocrine peptide 7B2 is required for peptide hormone processing in vivo and provides a novel mechanism for Cushing's syndrome. *Cell* 96:689-700, 1999.

135. Khovidhunkit W, RA Memon, JK Shigenaga, M Pang, M Schambelan, K Mulligan, KR Feingold, C Grunfeld: Plasma platelet-activating factor acetylhydrolase activity in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. *Metabolism* 48:1524-1531, 1999.

Journals

136. Mulligan K, VW Tai, M Schambelan: Use of growth hormone and other anabolic agents in AIDS wasting. *J Paren Enteral Nutr* 23 (Suppl 6):S202-209, 1999.

137. Mulligan K, C Grunfeld, VW Tai, H Algren, M Pang, DN Chernoff, JC Lo, M Schambelan: Hyperlipidemia and insulin resistance are induced by protease inhibitors independent of changes in body composition in patients with HIV infection. *J Acquir Immune Defic Syndr* 23:35-43, 2000.

138. Giacchetti G, LA Sechi, CA Griffin, BR Don, F Mantero, M Schambelan: The tissue-renin-angiotensin system in rats with fructose-induced hypertension: overexpression of type 1 angiotensin II receptor in adipose tissue. *J Hypertens* 18:695-702, 2000.

139. Kaplan G, S Thomas, DS Fierer, K Mulligan, PA Haslett, WJ Fessel, LG Smith, KA Kook, D Stirling, M Schambelan: Thalidomide for the treatment of AIDS-associated wasting. *AIDS Res Hum Retroviruses* 16:1345-1355, 2000.

140. Mulligan K, VW Tai, H Algren, DI Abrams, RJ Leiser, JC Lo, M Schambelan: Altered fat distribution in HIV-positive men on nucleoside analog reverse transcriptase inhibitor therapy. *J Acquire Immune Defic Syndr Retrovirol* 26:443-448, 2001.

141. Noor M, JC Lo, K Mulligan, J-M Schwarz, R Halvorsen, M Schambelan, C Grunfeld: Metabolic effects of indinavir in healthy HIV seronegative men. *AIDS* 15:F11-F18, 2001.

142. Lo JC, M Schambelan: Reproductive function in human immunodeficiency virus infection. *J Clin Endocrinol Metab* 86:2338-2343, 2001.

143. Lo JC, K Mulligan, M Noor, J-M Schwarz, RA Halvorsen, C Grunfeld, M Schambelan: The effects of recombinant human growth hormone on body composition and glucose metabolism in HIV-infected patients with fat accumulation. *J Clin Endocrinol Metab* 86:3480-3487, 2001.

144. Schwarz J-M, K Mulligan, J Lee, M Wen, MA Noor, C Grunfeld, M Schambelan: Effects of recombinant human growth hormone on hepatic lipid and carbohydrate metabolism in HIV-infected patients with fat accumulation. *J Clin Endocrinol Metab* 87:942-945, 2002.

145. Noor MA, T Seneviratne, FT Aweeka, JC Lo, J-M Schwarz, K Mulligan, M Schambelan, C Grunfeld: The HIV protease inhibitor indinivir acutely inhibits insulin-stimulated glucose disposal: a randomized, placebo-controlled study *AIDS* 16:F1-F8, 2002.

Journals

146. Napolitano LA, JC Lo, MB Gotway, K Mulligan, JD Barbour, D Schmidt, RA Halvorsen, CA Stoddart, M Schambelan, JM McCune: Increased thymic mass and circulating naïve CD4+ T cell counts in HIV-1 infected patients treated with growth hormone *AIDS* 16:1103-1111, 2002.

147. Tai V, M Schambelan, H Algren, C Shayevich, K Mulligan: Effects of recombinant human growth hormone on fat distribution in patients with HIV-associated wasting. *Clin Infect Dis* 35:1258-1262, 2002.

148. Mulligan K, M Schambelan: Anabolic treatment with GH, IGF-I, or anabolic steroids in patients with HIV-associated wasting. *Int J Cardiology* 85:151-159, 2002.

149. Schambelan M, CA Benson, A Carr, JS Currier, MP Dube, JG Gerber, SJ Grinspoon, C Grunfeld, DP Kotler, K Mulligan, WG Powderly, MS Saag: Management of metabolic complications associated with antiretroviral therapy for HIV-1 infection: recommendations of an International AIDS Society – USA panel. *J Acquire Immune Defic Syndr* 257-275, 2002.

150. Abrams DI, RJ Leiser, JF Hilton, SB Shade, TA Elbeik, FT Aweeka, NL Benowitz, BM Bredt, TF Mitchell, K Mulligan, JM McCune, M Schambelan: Short-term effects of cannabinoids in patients with human immunodeficiency virus-1 infection (submitted).

APPEARS THIS WAY
ON ORIGINAL

Book Chapters

1. Biglieri EG, JR Stockigt, RD Colline, M Schambelan: Mineralocorticoid hypertension: recognition and results of treatment. In: Hypertension 1972, J Genest (ed). Berlin: Springer Verlag, 1972, pp 319-325.

2. Biglieri EG, M Schambelan: Management of primary aldosteronism. In: Hypertension: Mechanisms and Management, G Onesti, KE Kim, and JH Moyer (eds). New York: Grune & Stratton, Inc, 1973, pp 493-498.

3. Biglieri EG, JR Stockigt, M Schambelan, RD Collins: Secondary hyperaldosteronism. In: Handbook of Experimental Pharmacology, O Eichler, et al. (eds), Vol 37. Angiotensin, FM Bumpus and IH Page (eds). Heidelberg: Springer-Verlag, 1974, pp 283-297.

4. Biglieri EG, JR Stockigt, M Schambelan: Adrenal mineralocorticoid hormones causing hypertension. In: Hypertension Manual: Mechanics, Methods, Rearrangements, JH Laragh (ed.). New York: Yorke Medical Books, 1974, pp 461-483.

5. Biglieri EG, M Schambelan, N Brust, B Chang, S Thomas: The mineralocorticoid hormones and hypertension. In: Hypertension. Current Problems, A Distler and HP Wolff (eds). Stuttgart: Georg Thieme Verlag, 1974, pp 96-106.

6. Schambelan M, N Brust, B Chang, EG Biglieri: Aldosterone production in low renin hypertensive states: response to spironolactone therapy. In: Mechanism of Hypertension, MP Sambhi (ed). Amsterdam: Excerpta Medica, 1974, pp 187-192.

7. Schambelan M, EG Biglieri: Hypertension and the role of the renin- angiotensin-aldosterone system in renal failure. In: The Kidney, BM Brenner and FC Rector Jr (eds). Philadelphia: WB Saunders Company, 1976, pp 1486-1514.

8. Sebastian A, HN Hulter, M Schambelan: Renal hyperchloremic acidosis with hyperkalemia: type 4 renal tubular acidosis (RTA). In: Proceedings of the VIIth International Congress of Nephrology, R Barcelo, M Bergeron, S Carriere, JH Dirks, K Drummond, RD Guttman, G Lemieux, JG Mongeau and JF Seely (eds). Basel: S Karger, 1978, pp 351-360.

9. Schambelan M, A Sebastian, HN Hulter: Mineralocorticoid excess and deficiency syndromes. In: Contemporary Issues in Nephrology, Vol 2. Acid Base and Potassium Homeostasis, BM Brenner and JH Stein (eds). New York: Churchill Livingstone, 1978, pp 232-268.

10. Schambelan M, JR Stockigt: Pathophysiology of the renin-angiotensin system. In: Contemporary Issues in Nephrology, Vol 4. Selected Topics in Hormonal Function, BM Brenner and JH Stein (eds). New York: Churchill Livingstone, 1979, pp 1-39.

11. Benowitz NL, WK Rogers, M Schambelan, M Wilson: Adrenergic and cardiovascular effects of disulfiram in man. In: Catecholamines: Basic and Clinnical Frontiers, E Usdin, IJ Kopin, and J Bachras (eds), Vol 2. New York: Pergamon Press, 1979, pp 1536-1538.

Book Chapters

12. Rost CR, M Schambelan: Hyperaldosteronism. In: Current Diagnosis, 6th ed, HF Conn (ed) Philadelphia: WB Saunders Co, 1980, pp 774-778.

13. Schambelan M, D Perloff: Renovascular and renal parenchymal hypertension. In: The Kidney, 2nd ed, BM Brenner and FC Rector Jr (eds). Philadelphia: WB Saunders Co, 1981, pp 1719-1741.

14. Perloff D, M Schambelan: Renovascular hypertension. In: Clinics in Endocrinology and Metabolism. EG Biglieri and M Schambelan (eds). London: WB Saunders Co, Ltd, Vol 10, 1981, pp 513-535.

15. Biglieri EG, M Schambelan (eds.): Clinics in Endocrinology and Metabolism. London: WB Saunders Co, Ltd, 1981, pp 656.

16. Sebastian A, M Schambelan, HN Hulter, I Kurtz, RE Hernandez, RC Morris Jr, EG Biglieri: Acid-base and electrolyte disorders associated with adrenal disease. In: Fluid, Electrolyte and Acid-base Disorders. A Arief and R DeFronzo (eds). Churchill Livingstone, Inc, 1985, p 893-932.

17. Sebastian A, M Schambelan, HN Hulter, T Maher, I Kurtz, EG Biglieri, FC Rector Jr, RC Morris Jr: Hyperkalemic renal tubular acidosis. In: Renal Tubular Disorders. V Buckalew and H Gonick (eds). Marcel Decker Publishers, New York, 1985, pp 307-356.

18. Sebastian A, RE Hernandez, M Schambelan: Disorders of renal handling of potassium. In: The Kidney, 3rd ed, BM Brenner and FC Rector Jr (eds). Philadelphia: WB Saunders Co, 1985 pp 519-549.

19. Schambelan M, A Sebastian: Hypoaldosteronism. In: CurrentTherapy in Endocrinology and Metabolism. DT Krieger and CW Bardin (eds). BC Decker, Inc, Philadelphia, 1985, pp 122-125.

20. Schambelan M, A Sebastian: Adrenal gland. In: Cecil Essentials of Medicine, TE Andreoli, CCJ Carpenter, F Plum, and LH Smith Jr (eds). Philadelphia: WB Saunders Co, 1986, pp 460-472.

21. Schambelan M: Hypothalamic-pituitary axis. In: Cecil Essentials of Medicine, TE Andreoli, CCJ Carpenter, F Plum, and LH Smith Jr (eds). Philadelphia: WB Saunders Co, 1986, pp 442-449.

22. Schambelan M, A Sebastian: States of aldosterone deficiency or pseudodeficiency. In: Hormone Resistance and Other Endocrine Paradoxes, MP Cohen, and P Foa (eds) New York: Springer-Verlag, Inc, 1987, pp 204-230.

Book Chapters

23. Schambelan M, BR Don, GA Kaysen, S Blake: Abnormalities of glomerular eicosanoid metabolism in states of glomerular hyperfiltration. In: Advances in Experimental Medicine and Biology (Vol 259). Renal Eicosanoids. MJ Dunn, C Patrono, and GA Cinotti (eds) New York: Plenum, pp 275-304, 1989.

24. Schambelan M: Hypothalamic-pituitary axis. In: Cecil Essentials of Medicine, 2nd ed, TE Andreoli, CCJ Carpenter, LH Smith Jr, and F Plum (eds). Philadelphia: WB Saunders Co, 1990, pp 448-455.

25. Schambelan M, A Sebastian: Adrenal gland. In: Cecil Essentials of Medicine, 2nd ed, TE Andreoli, CCJ Carpenter, LH Smith Jr, and F Plum (eds). Philadelphia: WB Saunders Co, 1990, pp 466-478.

26. Schambelan M: Hypothalamic-pituitary axis. In: Cecil Essentials of Medicine, 3rd ed, TE Andreoli, CCJ Carpenter, LH Smith Jr, and F Plum (eds). Philadelphia: WB Saunders Co, 1993, pp 462-470.

27. Schambelan M, A Sebastian: Adrenal gland. In: Cecil Essentials of Medicine, 3rd ed, TE Andreoli, CCJ Carpenter, LH Smith Jr, and F Plum (eds). Philadelphia: WB Saunders Co 1993, pp 481-492.

28. Don BR, M Schambelan: Adrenal cortical hypertension: pathophysiology. In: Hypertension Primer. JL Izzo and H Black (eds) 1993, pp 104-106.

29. Schambelan M, C Grunfeld: Endocrine abnormalities associated with HIV infection and AIDS. In: Textbook of AIDS Medicine. S Broder, TC Merrigan Jr, and D Bolognesi (eds). Baltimore: Williams and Wilkins 1994, pp 626-636.

30. Grunfeld C, M Schambelan: The wasting syndrome in AIDS: pathophysiology and treatment. In: Textbook of AIDS Medicine. S Broder, TC Merrigan Jr, and D Bolognesi (eds). Baltimore: Williams and Wilkins 1994, pp 637-649.

31. Schambelan M, C Grunfeld: Endocrinologic manifestations of HIV infection. In: The Medical Management of AIDS, 4th ed, MA Sande, and PA Volberding (eds). Philadelphia: WB Saunders Co, 1995, pp 345-357.

32. Mulligan K, C Grunfeld, MK Hellerstein, RA Neese, M Schambelan: Effects of recombinant human growth hormone on body composition and metabolism in HIV-associated wasting. In: Proceedings of GHRH, GH, and IGF-I: Basic and Clinical Advances. MR Blackman, SM Harmann, J Roth, and JR Shapiro (eds). New York:Springer-Verlag, Inc, 1995

33. Don BR, EG Biglieri, M Schambelan: Endocrine hypertension. In: Basic and Clinical Endocrinology, 5th ed. FS Greenspan and GJ Strewler (eds). Stanford, CN: Appelton & Lange, 1997, pp. 359-380.

Book Chapters

34. Schambelan M, DE Sellmeyer, C Grunfeld: Endocrinologic manifestations of HIV infection. In: The Medical Management of AIDS, 5th ed, MA Sande and PA Volberding (eds). Philadelphia: WB Saunders Co, 1997, pp 257-267.

35. Sellmeyer DE, C Grunfeld, M Schambelan: Endocrine abnormalities associated with HIV infection and AIDS. In: Textbook of AIDS Medicine, 2nd ed. TC Merrigan, Jr, J Bartlett, and D Bolognesi (eds). Baltimore: Williams and Wilkins, 1999, pp 629-641.

36. Grunfeld C, M Schambelan: The wasting syndrome: pathophysiology and treatment. In: Textbook of AIDS medicine, 2nd ed, TC Merrigan, Jr, J Bartlett, and D Bolognesi (eds). Baltimore: Williams and Wilkins, 1999, pp 643-659.

37. Mulligan K, M Schambelan: Growth hormone and other pharmacologic interventions. In: Nutritional Aspects of HIV Infection, TL Miller and SL Gorbach (eds). London: Arnold Press, 1999, pp 169-178.

38. Mulligan K, M Schambelan: Wasting. In: The AIDS Knowledge Base. PT Cohen, MA Sande, and PA Volberding (eds). Philadelphia: Lipincott Williams & Wilkins, 1999, pp 403-413.

39. Lo J, M Schambelan: Endocrine disease. In: AIDS Therapy, R Dolin, H Masur, and M Saag (eds). New York: Churchill Livingstone, 1999, pp 740-751.

40. Schambelan M, DE Sellmeyer, C Grunfeld: Wasting and endocrinologic manifestations of HIV infection. In: The Medical Management of AIDS, 6th ed, MA Sande and P Volberding (eds). Philadelphia: WB Saunders Co, pp 285-296, 1999.

41. Mulligan K, M Schambelan: Growth hormone in AIDS. In: Human Growth Hormone: Basic and Clinical Research. MO Thorner and RG Smith (eds). Totowa, NJ: Humana Press, Inc., pp 285-295, 2000.

42. Don BR, M Schambelan: Endocrine hypertension. In: Basic and Clinical Endocrinology, 6th ed. FS Greenspan and D Gardner (eds). Stanford, CN: Appelton & Lange, 2001.

43. Lo JC, M Schambelan: Adrenal, gonadal, and thyroid disorders. In: AIDS Therapy, R Dolin, H Masur (eds), 2nd edition. New York: Churchill Livingston (in press).

Recent Abstracts

150. Tai VW, K Mulligan, H Algren, C Shayevich, N Patterson, S Holmes-Schambelan, M Schambelan: Effects of growth hormone on regional fat distribution in patients with HIV-associated wasting. *American Society for Parenteral and Enteral Nutrition 24th Clinical Congress, Nashville*, TN, 2000.

151. Mulligan K, VW Tai, JC Lo, H Algren, DI Abrams, N Patterson, M Schambelan. Altered fat distribution in men on RT inhibitors (RTIs). *7th Conf on Retroviruses and Opportunistic Infections*, San Francisco, CA, 2000.

152. Lo JC, K Mulligan, C Grunfeld, ES Daar, VW Tai, M Pang, J Pitt, B Chang, M Schambelan: The effect of recombinant human growth hormone on adrenal and gonadal steroids in patients with HIV-associated wasting. *Endocrine Society 82nd Annual Meeting*, Toronto, 2000.

153. Noor M, J Lo, K Mulligan, R Halvorsen, J-M Schwarz, M Schambelan, C Grunfeld: Metabolic effects of indinavir in healthy HIV seronegative subjects. *2nd International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV*, Toronto, 2000.

154. Lo JC, K Mulligan, M Noor, J-M Schwarz, C Grunfeld, M Schambelan: The effects of recombinant human growth hormone (GH) on glucose metabolism and body composition in HIV-positive subjects with fat accumulation (FA) syndromes. *2nd International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV*, Toronto, 2000.

155. Schambelan M, R Zackin, K Mulligan, F Sattler, M Chesney, M Stevens, L Edwards, M Egorin, J Von Roenn for the ACTG 313 Study Team. Effect of testosterone (T) on the response to megestrol acetate (MA) in patients with HIV-associated wasting: A randomized, double-blind placebo-controlled trial (ACTG 313). *8th Conf on Retroviruses and Opportunistic Infections*, Chicago, IL 2001.

156. Mulligan K, DI Abrams, RJ Leiser, M Schambelan: Body composition changes in HIV-infected men consuming self-selected diets during a placebo-controlled inpatient study of cannabinoids. *8th Conf on Retroviruses and Opportunistic Infections*, Chicago, IL 2001.

157. Mulligan K, H Algren, M Schambelan: Nandrolone decanoate in HIV-positive men with wasting: a randomized, double-blind, placebo-controlled study. *International Conference on Nutrition and HIV Infection*, Cannes, France, 2001.

158. Napolitano L, J Lo, M Gotway, K Mulligan, J Barbour, D Schmidt, R Grant, R. Halvorsen, M Schambelan, JM McCune: Increased thymic mass and circulating naïve CD4+ T cell counts in HIV-1-infected adults treated with growth hormone. *9th Conference on Retroviruses and Opportunistic Infections*, Seattle, 2002, p. 244.